ReviewJournal of diabetes research2017
Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?
Review in Journal of diabetes research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Ferroptosis and ferritinophagy in diabetes complications.Molecular metabolism · 2022Pooled it
- Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.Diabetology & metabolic syndrome · 2026Review
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses.Molecular neurobiology · 2026Article
- Article
- Residual cholesterol correlates with mild cognitive impairment, particularly for executive dysfunction among male individuals with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Review
- Review
- Review
- PCSK9 deficiency promotes the development of peripheral neuropathy.JCI insight · 2025Article
- Lipid Transporter ABCA1 in Diabetic Polyneuropathy: Potential Mediation by Circulating Metabolites.Journal of pain research · 2025Article
- Association of long noncoding RNA MEG3 genetic variants with the risk of diabetic neuropathy.International journal of medical sciences · 2025Article
- Causal Association Between Cholesterol-Lowering Drugs and Diabetic Microvascular Complications: A Drug-Target Mendelian Randomization Study.Journal of diabetes research · 2025Article
- Topical and oral peroxisome proliferator-activated receptor-α agonist ameliorates diabetic corneal neuropathy.Scientific reports · 2024Article
- The association between variability of risk factors and complications in type 2 diabetes mellitus: a retrospective study.Scientific reports · 2024Article
- The mediating role of HbA1c in the association between elevated low-density lipoprotein cholesterol levels and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus.Lipids in health and disease · 2023Article
- Observational
- Multi-omics analysis revealed the role of CYP1A2 in the induction of mechanical allodynia in type 1 diabetes.Frontiers in genetics · 2023Article
- Statins Neuromuscular Adverse Effects.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic polyneuropathy (DPN) encompasses multiple syndromes with a common pathogenesis. Glycemic control shows a limited correlation with DPN, arguing in favor of major involvement of other factors, one of which is alterations of lipid and lipoprotein metabolism. Consistent associations have been found between plasma triglycerides/remnant lipoproteins and the risk of DPN. Studies in cultured nerve tissue or in murine models of diabetes have unveiled mechanisms linking lipid metabolism to DPN. Deficient insulin action increases fatty acids flux to nerve cells, inducing mitochondrial dysfunction, anomalous protein kinase C signaling, and perturbations in the physicochemical properties of the plasma membrane. Oxidized low-density lipoproteins bind to cellular receptors and promote generation of reactive oxygen species, worsening mitochondrial function and altering the electrical properties of neurons. Supplementation with specific fatty acids has led to prevention or reversal of different modalities of DPN in animal models. Post hoc and secondary analyses of clinical trials have found benefits of cholesterol reducing (statins and ezetimibe), triglyceride-reducing (fibrates), or lipid antioxidant (thioctic acid) therapies over the progression and severity of DPN. However, these findings are mostly hypothesis-generating. Randomized trials are warranted in which the impact of intensive plasma lipids normalization on DPN outcomes is specifically evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.